Status: Recruiting
Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction
This clinical study will utilize a new cell therapy approach (Human embryonic stem cells derived cardiomyocytes or hESC-CMs) to improve survival and cardiac function in patients with chronic left ventricular dysfunction secondary to MI (Myocardial Infarction).
Participants needed: 18
Trial details
Phase: Phase 1Age: 21-80Biological sex: AllType: InterventionalSponsor: Joseph C. WuUpdated: Sep 29, 2025Locations: 1
Eligibility criteria
Be ≥ 21 and < 80 years of age. [+8]
Have a baseline glomerular filtration rate < 35 ml/min/1.73 m2 [+20]